Biologics : Targets & Therapy最新文献

筛选
英文 中文
Biosimilars in Pediatric IBD: Updated Considerations for Disease Management. 儿科IBD的生物仿制药:疾病管理的最新考虑。
IF 4
Biologics : Targets & Therapy Pub Date : 2022-06-13 eCollection Date: 2022-01-01 DOI: 10.2147/BTT.S367032
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano
{"title":"Biosimilars in Pediatric IBD: Updated Considerations for Disease Management.","authors":"Valeria Dipasquale,&nbsp;Ugo Cucinotta,&nbsp;Claudio Romano","doi":"10.2147/BTT.S367032","DOIUrl":"https://doi.org/10.2147/BTT.S367032","url":null,"abstract":"<p><p>Biologic drugs have significantly modified the pharmacological management of several chronic conditions, including inflammatory bowel diseases (IBD). By contrast, in the last two decades, biologics have been associated with increased direct medical costs. As patents for the reference drugs have expired, the development and commercialization of biosimilars through abbreviated licensing pathways represented an affordable alternative in patients fulfilling the indication for biologics. A growing body of evidence, first in adults and then in the pediatric age group too, has provided reassuring data in terms of efficacy and safety of biosimilars both in naïve patients and in those previously on reference drugs who had to switch to the biosimilar. This review summarizes the currently available evidence for biosimilar use in IBD, with a focus on pediatric IBD. The most common practical approaches to biosimilar use in the pediatric clinical settings are also discussed.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":" ","pages":"57-66"},"PeriodicalIF":4.0,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/a7/btt-16-57.PMC9205321.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40041672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis 单克隆抗体治疗间质性膀胱炎
IF 4
Biologics : Targets & Therapy Pub Date : 2022-05-20 DOI: 10.2147/BTT.S290286
I. Mykoniatis, Stavros Tsiakaras, M. Samarinas, A. Anastasiadis, E. N. Symeonidis, P. Sountoulides
{"title":"Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis","authors":"I. Mykoniatis, Stavros Tsiakaras, M. Samarinas, A. Anastasiadis, E. N. Symeonidis, P. Sountoulides","doi":"10.2147/BTT.S290286","DOIUrl":"https://doi.org/10.2147/BTT.S290286","url":null,"abstract":"Abstract An emerging theory regarding the potentially autoimmune nature of painful bladder syndrome/interstitial cystitis (PBS/IC) had led to several studies being conducted to assess the possible therapeutic effect of immunotherapeutic options for PBS/IC. This review presents the available evidence regarding the potential autoimmunity-based pathogenesis of PBS/IC and focuses on a main representative of the immunotherapeutic modalities for PBS/IC, aiming to summarize, evaluate, and present available data regarding the potential therapeutic role of monoclonal antibodies for PBS/IC patients. A non-systematic narrative and interpretative literature review was performed. The monoclonal antibodies included in the review were the anti-tumor necrosis factor-α (anti-TNF-α) agents adalimumab, which showed no difference compared to placebo, and certolizumab pegol, which showed statistically important differences in all outcome measures compared to placebo at the 18-week follow-up visit. Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 1","pages":"47 - 55"},"PeriodicalIF":4.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47970705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response T细胞靶向代谢重编程增强抗肿瘤反应
IF 4
Biologics : Targets & Therapy Pub Date : 2022-05-01 DOI: 10.2147/BTT.S365490
Y. T. Dabi, H. Andualem, S. T. Degechisa, S. T. Gizaw
{"title":"Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response","authors":"Y. T. Dabi, H. Andualem, S. T. Degechisa, S. T. Gizaw","doi":"10.2147/BTT.S365490","DOIUrl":"https://doi.org/10.2147/BTT.S365490","url":null,"abstract":"Abstract Cancer immunotherapy is an effective treatment option against cancer. One of the approaches of cancer immunotherapy is the modification of T cell-based anti-tumor immune responses. T-cells, a type of adaptive immune response cells responsible for cell-mediated immunity, have long been recognized as key regulators of immune-mediated anti-tumor immunity. T-cell activities have been reported to be suppressed or enhanced by changes in cell metabolism. Moreover, metabolic reprogramming during activation of T cells is required for the development of distinct differentiation profiles of these cells, which may allow the development of long-term cell-mediated anti-tumor immunity. However, T cells have been shown to undergo metabolic exhaustion in tumor microenvironment (TME) as it poses several obstacles to their function. Applications of several mechanistic solutions to improve the efficacy of T cell-based therapies including chimeric antigen receptor (CAR) T cell therapy are yet to be determined. Modifying the metabolic properties of these cells and employing them in cancer immunotherapy is a potential strategy for improving their anti-tumor activity and therapeutic efficacy. To give an insight, in this review paper, we endeavoured to cover metabolic reprogramming in cancer and T cells, signalling mechanisms involved in immuno-metabolic regulation, the effects of the TME on T cell metabolic fitness, and targeting metabolic reprogramming of T cells for an enhanced anti-tumor response.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 1","pages":"35 - 45"},"PeriodicalIF":4.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42016582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Progress in Biological Therapies for Adult-Onset Still’s Disease 成人发病斯蒂尔氏病的生物治疗进展
IF 4
Biologics : Targets & Therapy Pub Date : 2022-04-01 DOI: 10.2147/BTT.S290329
P. Galozzi, S. Bindoli, A. Doria, P. Sfriso
{"title":"Progress in Biological Therapies for Adult-Onset Still’s Disease","authors":"P. Galozzi, S. Bindoli, A. Doria, P. Sfriso","doi":"10.2147/BTT.S290329","DOIUrl":"https://doi.org/10.2147/BTT.S290329","url":null,"abstract":"Abstract Adult-onset Still’s disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting forms with mild symptoms to life-threatening cases and presents clinical and biological similarities with the juvenile form (sJIA). Nowadays, the advances in biologic agents no longer limit the treatment to NSAIDs, glucocorticoids, or conventional synthetic DMARDs. The blockade of IL-1 and IL-6 is effective in the treatment of systemic and articular inflammation of AOSD patients; however, novel compounds with different properties and targets are now available and others are being studied. In this review, starting from the pathogenesis of AOSD, we summarized the current and emerging biological therapies, possible effective agents for achieving AOSD control and remission.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 1","pages":"21 - 34"},"PeriodicalIF":4.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47547261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Continuous Use of Etanercept During Pregnancy Does Not Affect TNF-Alpha Levels in Umbilical Cord Blood 妊娠期持续使用依那西普不会影响脐血中TNF-α水平
IF 4
Biologics : Targets & Therapy Pub Date : 2022-03-01 DOI: 10.2147/BTT.S358449
Masayuki Nishide, Mayu Yagita, A. Kumanogoh
{"title":"Continuous Use of Etanercept During Pregnancy Does Not Affect TNF-Alpha Levels in Umbilical Cord Blood","authors":"Masayuki Nishide, Mayu Yagita, A. Kumanogoh","doi":"10.2147/BTT.S358449","DOIUrl":"https://doi.org/10.2147/BTT.S358449","url":null,"abstract":"Abstract TNF-alpha-targeted therapies during pregnancy is a topic of interest in rheumatology. Etanercept (ETN) is expected to have lower transplacental transfer, however, clinical evidence is lacking on the usefulness and safeness of continuing etanercept throughout pregnancy. We here described the first reported case of relapsing polychondritis where continuous use of ETN throughout pregnancy was required. The patient was a pregnant Japanese woman who presented with bilateral ear cartilage redness, swelling, saddle nose and severe subglottic oedema. Due to severe systemic and life-threatened disease, we decided to continue using ETN throughout pregnancy and resulted in successful vaginal delivery. The treatment with ETN was successful and TNF-alpha levels in umbilical cord blood were not affected. The infant did not have any signs of chondritis although levels of anti-type 2 collagen antibodies in maternal and umbilical cord blood were similar, suggesting that anti-type 2 collagen antibodies crossed the placenta. This case is an important clinical experience that strengthens the safety to continue ETN during the entire pregnancy if necessary.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 1","pages":"17 - 19"},"PeriodicalIF":4.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46134943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Anti-Tumor Necrosis Factor-α Therapy Against Intestinal Behçet's Disease Complicated by Recurrent Enterocutaneous Fistulae. 抗肿瘤坏死因子-α治疗肠道behalet病并发复发性肠皮瘘的疗效观察。
IF 4
Biologics : Targets & Therapy Pub Date : 2022-02-02 eCollection Date: 2022-01-01 DOI: 10.2147/BTT.S348300
Hitomi Kashima, Satohiro Matsumoto, Shu Kojima, Yudai Koito, Takaya Miura, Takehiro Ishii, Hirosato Mashima
{"title":"Efficacy of Anti-Tumor Necrosis Factor-α Therapy Against Intestinal Behçet's Disease Complicated by Recurrent Enterocutaneous Fistulae.","authors":"Hitomi Kashima,&nbsp;Satohiro Matsumoto,&nbsp;Shu Kojima,&nbsp;Yudai Koito,&nbsp;Takaya Miura,&nbsp;Takehiro Ishii,&nbsp;Hirosato Mashima","doi":"10.2147/BTT.S348300","DOIUrl":"https://doi.org/10.2147/BTT.S348300","url":null,"abstract":"<p><p>A 55-year-old man presented with recurrent ulcers and an enterocutaneous fistula at the anastomotic site after surgery for an ileovesical fistula and was diagnosed with intestinal Behçet's disease after undergoing surgery for enterocutaneous fistulae twice. The patient was transferred to our hospital because of recurrent enterocutaneous fistulae. He had a history of recurrent oral aphthous ulcers, folliculitis, and epididymitis and met the diagnostic/classification criteria for incomplete Behçet's disease and thus was diagnosed as having intestinal Behçet's disease. Remission induction therapy with steroids was administered for an ileal ulcer and an enterocutaneous fistula, and adalimumab was initiated for maintenance therapy. The fistula was closed, and the clinical course was favorable. Two months after initiating adalimumab, a subcutaneous abscess was detected at the site of the enterocutaneous fistula scar, and relapse of intestinal Behçet's disease was suspected. Steroids were re-administered for remission induction, followed by maintenance therapy, for which adalimumab was switched to infliximab. No relapse was detected after steroid withdrawal. No therapeutic strategies have been established for intestinal Behçet's disease. Moreover, there have been very few reports on therapeutic strategies and postoperative maintenance therapy for enterocutaneous fistulae. We thus consider this case valuable.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":4.0,"publicationDate":"2022-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/e1/btt-16-1.PMC8818548.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39904133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon 黎巴嫩癌症转移性结直肠癌患者首次贝伐单抗联合化疗的非常规多中心研究
IF 4
Biologics : Targets & Therapy Pub Date : 2022-02-01 DOI: 10.2147/BTT.S340525
S. Temraz, F. Nasr, J. Kattan, D. Abigerges, W. Moukadem, F. Farhat, L. Maatouk, G. Chahine, A. Shamseddine
{"title":"A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon","authors":"S. Temraz, F. Nasr, J. Kattan, D. Abigerges, W. Moukadem, F. Farhat, L. Maatouk, G. Chahine, A. Shamseddine","doi":"10.2147/BTT.S340525","DOIUrl":"https://doi.org/10.2147/BTT.S340525","url":null,"abstract":"Purpose When combined with chemotherapy, bevacizumab improves progression-free survival (PFS) in metastatic colorectal cancer (mCRC). This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line chemotherapy in a real-world setting in Lebanon. Patients and Methods A non-interventionaL multicenter study of first-LIne AVastin® (bevacizumab) in combination with chEmotherapy in patients with metastatic colorectal cancer (LLIVE) is a multicenter, prospective, Lebanon-based, observational study that enrolled mCRC patients who received first-line bevacizumab plus chemotherapy combination. The primary end point of the study was PFS. Secondary endpoints comprised the overall response rate (ORR) and the safety and tolerability of bevacizumab. Results A total of 196 patients were enrolled between July 2010 and August 2013. The median duration of follow-up was 11 months. Median duration of bevacizumab treatment was 4 months with FOLFOX being the chiefly chemotherapy regimen used in the first-line setting (26%). Median PFS was 8.22 months (95% confidence interval (CI): 7.005–9.443). The ORR was 50.3% (complete response 7.5%, partial response 42.8%). The most common adverse event encountered was hypertension (28%) followed by epistaxis (4.8%), diarrhea (4%), anemia (4%) and headache (4%). Grade 3/4 adverse events occurred in 15.2% of patients. Conclusion The trial further substantiated the efficacy and safety of bevacizumab and chemotherapy in the first-line treatment of mCRC patients in Lebanon.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 1","pages":"7 - 15"},"PeriodicalIF":4.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48063634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances. 炎症性肠病的分子病理生理学研究进展
IF 4
Biologics : Targets & Therapy Pub Date : 2022-01-01 DOI: 10.2147/BTT.S380027
Maheeba Abdulla, Nafeesa Mohammed
{"title":"A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances.","authors":"Maheeba Abdulla,&nbsp;Nafeesa Mohammed","doi":"10.2147/BTT.S380027","DOIUrl":"https://doi.org/10.2147/BTT.S380027","url":null,"abstract":"<p><p>Inflammatory bowel diseases are considered immune disorders with a complex genetic architecture involving constantly changing endogenous and exogenous factors. The rapid evolution of genomic technologies and the emergence of newly discovered molecular actors are compelling the research community to reevaluate the knowledge and molecular processes. The human intestinal tract contains intestinal human microbiota consisting of commensal, pathogenic, and symbiotic strains leading to immune responses that can contribute and lead to both systemic and intestinal disorders including IBD. In this review, we attempted to highlight some updates of the new IBD features related to genomics, microbiota, new emerging therapies and some major established IBD risk factors.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"16 ","pages":"129-140"},"PeriodicalIF":4.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/ae/btt-16-129.PMC9481278.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. 银屑病关节炎患者在Secukinumab失败后使用Ixekizumab治疗:来自耐药人群的真实经验
IF 4
Biologics : Targets & Therapy Pub Date : 2021-11-18 eCollection Date: 2021-01-01 DOI: 10.2147/BTT.S326792
Julia Berman, Victoria Furer, Mark Berman, Ofer Isakov, Devy Zisman, Amir Haddad, Ori Elkayam
{"title":"Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population.","authors":"Julia Berman,&nbsp;Victoria Furer,&nbsp;Mark Berman,&nbsp;Ofer Isakov,&nbsp;Devy Zisman,&nbsp;Amir Haddad,&nbsp;Ori Elkayam","doi":"10.2147/BTT.S326792","DOIUrl":"https://doi.org/10.2147/BTT.S326792","url":null,"abstract":"<p><strong>Objective: </strong>To assess the clinical response to ixekizumab following secukinumab failure in patients with psoriatic arthritis.</p><p><strong>Methods: </strong>A retrospective multi-center observational study included psoriatic arthritis (PsA) patients with a history of treatment with secukinumab, further treated with ixekizumab. Primary endpoint was primary response to treatment (drug survival > 6 months); secondary endpoints were changes in disease activity indices from initiation of ixekizumab to 6 and 12 months later and overall drug survival.</p><p><strong>Results: </strong>Of 23 PsA patients, 86% (n = 20) received more than two TNF inhibitors (TNFi). Median secukinumab treatment time was 15 months (IQR 10-21.5 months). Subsequently, 19 patients (83%) had a primary response to ixekizumab. Overall treatment duration during follow-up period for primary responders was 14 months (IQR 10-20.5). Reasons for ixekizumab cessation were worsening psoriasis (27%), peripheral arthritis (27%), both (47%), worsening of axial disease (13%), and adverse events (6%). Articular disease indices including Disease Activity Index for Psoriatic Arthritis (DAPSA), tender joints count (TJC) and Simplified Disease Activity Index (SDAI) were significantly lower at 6 and 12 months (DAPSA 1.5-2 levels reduction; p = 0.018 and 1-1.5 levels reduction; p = 0.031, respectively; TJC -2.16 [-4.0, -0.3]; p = 0.025 and -1.69 [-3.09, -0.28]; p = 0.022, respectively; SDAI -10.13 [-16.4, -3.8], p = 0.003 and -12.2 [-17.1, -7.2], p = 0.0002, respectively). PASI75 at 6 and 12 months was achieved by 63% and 57%, respectively, and PASI100 at 6 and 12 months by 31% and 21%, respectively.</p><p><strong>Conclusion: </strong>Patients with resistant PsA, including inadequate response to secukinumab, demonstrated a good response to ixekizumab, albeit limited on time. Within class switch from secukinumab to ixekizumab may be a plausible therapeutic option in PsA patients following secukinumab failure.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":" ","pages":"463-470"},"PeriodicalIF":4.0,"publicationDate":"2021-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/d3/btt-15-463.PMC8608411.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39656135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. 单克隆抗体治疗胃癌的研究进展
IF 4
Biologics : Targets & Therapy Pub Date : 2021-11-03 eCollection Date: 2021-01-01 DOI: 10.2147/BTT.S290323
Debora Basile, Francesca Simionato, Alessandro Cappetta, Silvio Ken Garattini, Giandomenico Roviello, Giuseppe Aprile
{"title":"State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer.","authors":"Debora Basile,&nbsp;Francesca Simionato,&nbsp;Alessandro Cappetta,&nbsp;Silvio Ken Garattini,&nbsp;Giandomenico Roviello,&nbsp;Giuseppe Aprile","doi":"10.2147/BTT.S290323","DOIUrl":"https://doi.org/10.2147/BTT.S290323","url":null,"abstract":"<p><p>Gastric cancer (GC) is a complex and heterogeneous disease with poor prognosis and limited available treatment options. During recent years, several molecular stratifications have been proposed to optimize the overall treatment strategy for GC patients. Breakthroughs in cancer biology and in molecular profiling through DNA and RNA sequencing are now opening novel landscapes, leading to the personalization of molecular matched therapy. In particular, therapies against HER2, Claudine 18.2, Fibroblast Growth Factor Receptors (FGFR), and other molecular alterations could significantly improve survival outcomes in the advance phase of the disease. Furthermore, immunotherapy with checkpoint inhibitors also represents a promising option in a selected population. Hoping that precision oncology will enter soon in clinical practice, our review describes the state of the art of many novel pathways and the current evidence supporting the use of monoclonal antibodies implicated in GC treatment.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":" ","pages":"451-462"},"PeriodicalIF":4.0,"publicationDate":"2021-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/d2/btt-15-451.PMC8572727.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39613261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信